NPM1 and acute myeloid leukemia: The impact of IDH1/2 mutations on AML prognosis is controversial, and depends on the specific AML subsets, i.e., normal karyotype or FLT3-WT/NPM1-WT, or treatment groups, i.e., standard intensive chemotherapy [5,6,15,16].